NCT06034275 is a Phase 1 clinical trial of VIP943 (QW) in Acute Myeloid Leukemia, sponsored by Vincerx Pharma, Inc..

Who is sponsoring NCT06034275?

NCT06034275 is sponsored by Vincerx Pharma, Inc..

What drugs are being tested in NCT06034275?

Interventions in NCT06034275: VIP943 (QW), VIP943 (BIW).

What condition does NCT06034275 study?

NCT06034275 studies Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome.

Is NCT06034275 still recruiting?

NCT06034275 is currently recruiting now. Last updated 15 November 2024.

Last reviewed 2024-11-15 · How we verify

NCT06034275

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Recruiting now Phase 1 Last updated 15 November 2024

What this trial tests

Phase 1 trial testing VIP943 (QW) in Acute Myeloid Leukemia in 36 participants. Currently enrolling.

Timeline

13 September 2023

Primary endpoint
30 May 2025

31 December 2025

Quick facts

Lead sponsor	Vincerx Pharma, Inc.
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	13 September 2023
Primary completion	30 May 2025
Estimated completion	31 December 2025
Sites	5 locations across United States

Drugs / interventions tested

VIP943 (QW) — full drug profile →
VIP943 (BIW) — full drug profile →

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
B-cell Acute Lymphoblastic Leukemia — all drugs for B-cell Acute Lymphoblastic Leukemia →
High-risk Myelodysplastic Syndrome — all drugs for High-risk Myelodysplastic Syndrome →

Sponsor

Vincerx Pharma, Inc. — full company profile →

Who can join

18 and older, any sex, with Acute Myeloid Leukemia or B-cell Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
Jen WY, Kantarjian H, Kadia TM, DiNardo CD, et al · · 2024 · cited 32× · PMID 38724457 · DOI 10.1111/bjh.19519
Legumain-Cleavable Top1i Antibody-Drug Conjugates without Self-Immolative Spacers Demonstrate Potent Antitumor Activity.
Ojo VT, Bianchi NA, Yi MZ, Chung SH, et al · · 2025 · cited 3× · PMID 41267393 · DOI 10.1021/acs.jmedchem.5c02681
Kinesin Spindle Protein (KIF11) in Mitosis and Cancer.
Silva JPN, Silva PMA, Bousbaa H. · · 2025 · PMID 41009541 · DOI 10.3390/ijms26188975

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other Vincerx Pharma, Inc. trials

Trials by the same sponsor.

NCT05712889 — Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer · Phase 1 · completed
NCT04978779 — A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome · Phase 1 · terminated
NCT02635672 — Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06034275 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vincerx Pharma, Inc.
Last refreshed: 15 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06034275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing